Advertisements
The ongoing shortage of glucagon-like peptide 1 receptor (GLP-1) agonists such as semaglutide (marketed as Wegovy and Ozempic) is a “major public health concern” that is unlikely to be resolved in 2024, the European Medicines Agency has warned.
Advertisements
Speaking at a briefing on 26 June on how the EU is tackling these shortages, the EMA’s executive director, Emer Cooke, said, “Despite our collective efforts the shortages continue and there are no instant solutions, and we don’t expect them to be resolved this year.”
Advertisements
As a result the EMA has issued recommendations for industry and healthcare professionals to try to reduce the negative effects of shortages on people with type 2 diabetes and obesity.1 These includes …
Advertisements
Advertisements
Advertisements
